{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0050024\nAge: 62\nGender: Male\nSample ID: P-0050024-T02-IM6\nGene Panel: IMPACT468\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nMET c.2937_3028+10del (p.X979_splice) - in 29.00% of 941 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nMET - nan (nan)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Capmatinib\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": \"MET exon 14 skipping mutation (c.2937_3028+10del, p.X979_splice)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213669s000lbl.pdf\"\n  }\n}"
}